182 related articles for article (PubMed ID: 32591597)
1. Evaluation of the therapeutic potential of Epigallocatechin-3-gallate (EGCG) via oral gavage in young adult Down syndrome mice.
Goodlett CR; Stringer M; LaCombe J; Patel R; Wallace JM; Roper RJ
Sci Rep; 2020 Jun; 10(1):10426. PubMed ID: 32591597
[TBL] [Abstract][Full Text] [Related]
2. Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes.
Stringer M; Abeysekera I; Thomas J; LaCombe J; Stancombe K; Stewart RJ; Dria KJ; Wallace JM; Goodlett CR; Roper RJ
Physiol Behav; 2017 Aug; 177():230-241. PubMed ID: 28478033
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of Epigallocatechin-3-gallate containing supplements on correcting skeletal defects in a Down syndrome mouse model.
Abeysekera I; Thomas J; Georgiadis TM; Berman AG; Hammond MA; Dria KJ; Wallace JM; Roper RJ
Mol Nutr Food Res; 2016 Apr; 60(4):717-726. PubMed ID: 26748562
[TBL] [Abstract][Full Text] [Related]
4. Increased dosage and treatment time of Epigallocatechin-3-gallate (EGCG) negatively affects skeletal parameters in normal mice and Down syndrome mouse models.
Jamal R; LaCombe J; Patel R; Blackwell M; Thomas JR; Sloan K; Wallace JM; Roper RJ
PLoS One; 2022; 17(2):e0264254. PubMed ID: 35196359
[TBL] [Abstract][Full Text] [Related]
5. Green tea extracts containing epigallocatechin-3-gallate modulate facial development in Down syndrome.
Starbuck JM; Llambrich S; Gonzàlez R; Albaigès J; Sarlé A; Wouters J; González A; Sevillano X; Sharpe J; De La Torre R; Dierssen M; Vande Velde G; Martínez-Abadías N
Sci Rep; 2021 Feb; 11(1):4715. PubMed ID: 33633179
[TBL] [Abstract][Full Text] [Related]
6. Low dose EGCG treatment beginning in adolescence does not improve cognitive impairment in a Down syndrome mouse model.
Stringer M; Abeysekera I; Dria KJ; Roper RJ; Goodlett CR
Pharmacol Biochem Behav; 2015 Nov; 138():70-9. PubMed ID: 26363314
[TBL] [Abstract][Full Text] [Related]
7. Short- and long-term effects of neonatal pharmacotherapy with epigallocatechin-3-gallate on hippocampal development in the Ts65Dn mouse model of Down syndrome.
Stagni F; Giacomini A; Emili M; Trazzi S; Guidi S; Sassi M; Ciani E; Rimondini R; Bartesaghi R
Neuroscience; 2016 Oct; 333():277-301. PubMed ID: 27457036
[TBL] [Abstract][Full Text] [Related]
8. Skeletal Deficits in Male and Female down Syndrome Model Mice Arise Independent of Normalized Dyrk1a Expression in Osteoblasts.
Thomas JR; Sloan K; Cave K; Wallace JM; Roper RJ
Genes (Basel); 2021 Oct; 12(11):. PubMed ID: 34828335
[TBL] [Abstract][Full Text] [Related]
9. Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans.
De la Torre R; De Sola S; Pons M; Duchon A; de Lagran MM; Farré M; Fitó M; Benejam B; Langohr K; Rodriguez J; Pujadas M; Bizot JC; Cuenca A; Janel N; Catuara S; Covas MI; Blehaut H; Herault Y; Delabar JM; Dierssen M
Mol Nutr Food Res; 2014 Feb; 58(2):278-88. PubMed ID: 24039182
[TBL] [Abstract][Full Text] [Related]
10. Influence of prenatal EGCG treatment and Dyrk1a dosage reduction on craniofacial features associated with Down syndrome.
McElyea SD; Starbuck JM; Tumbleson-Brink DM; Harrington E; Blazek JD; Ghoneima A; Kula K; Roper RJ
Hum Mol Genet; 2016 Nov; 25(22):4856-4869. PubMed ID: 28172997
[TBL] [Abstract][Full Text] [Related]
11. Sexually dimorphic DYRK1A overexpression on postnatal day 15 in the Ts65Dn mouse model of Down syndrome: Effects of pharmacological targeting on behavioral phenotypes.
Hawley LE; Prochaska F; Stringer M; Goodlett CR; Roper RJ
Pharmacol Biochem Behav; 2022 Jun; 217():173404. PubMed ID: 35576991
[TBL] [Abstract][Full Text] [Related]
12. Rescue of the abnormal skeletal phenotype in Ts65Dn Down syndrome mice using genetic and therapeutic modulation of trisomic Dyrk1a.
Blazek JD; Abeysekera I; Li J; Roper RJ
Hum Mol Genet; 2015 Oct; 24(20):5687-96. PubMed ID: 26206885
[TBL] [Abstract][Full Text] [Related]
13. Usage of and attitudes about green tea extract and Epigallocathechin-3-gallate (EGCG) as a therapy in individuals with Down syndrome.
Long R; Drawbaugh ML; Davis CM; Goodlett CR; Williams JR; Roper RJ
Complement Ther Med; 2019 Aug; 45():234-241. PubMed ID: 31331567
[TBL] [Abstract][Full Text] [Related]
14. Molecular Rescue of Dyrk1A Overexpression Alterations in Mice with Fontup
Gu Y; Moroy G; Paul JL; Rebillat AS; Dierssen M; de la Torre R; Cieuta-Walti C; Dairou J; Janel N
Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32092951
[TBL] [Abstract][Full Text] [Related]
15. Green Tea Catechins Modulate Skeletal Development with Effects Dependent on Dose, Time, and Structure in a down Syndrome Mouse Model.
Llambrich S; González-Colom R; Wouters J; Roldán J; Salassa S; Wouters K; Van Bulck V; Sharpe J; Callaerts-Vegh Z; Vande Velde G; Martínez-Abadías N
Nutrients; 2022 Oct; 14(19):. PubMed ID: 36235819
[TBL] [Abstract][Full Text] [Related]
16. The polyphenols resveratrol and epigallocatechin-3-gallate restore the severe impairment of mitochondria in hippocampal progenitor cells from a Down syndrome mouse model.
Valenti D; de Bari L; de Rasmo D; Signorile A; Henrion-Caude A; Contestabile A; Vacca RA
Biochim Biophys Acta; 2016 Jun; 1862(6):1093-104. PubMed ID: 26964795
[TBL] [Abstract][Full Text] [Related]
17. EGCG-like non-competitive inhibitor of DYRK1A rescues cognitive defect in a down syndrome model.
Delabar JM; Gomes MAGB; Fructuoso M; Sarrazin N; George N; Fleary-Roberts N; Sun H; Bui LC; Rodrigues-Lima F; Janel N; Dairou J; Maria EJ; Dodd RH; Cariou K; Potier MC
Eur J Med Chem; 2024 Feb; 265():116098. PubMed ID: 38171148
[TBL] [Abstract][Full Text] [Related]
18. Novel Epigenetic Regulation of Alpha-Synuclein Expression in Down Syndrome.
Ramakrishna N; Meeker HC; Brown WT
Mol Neurobiol; 2016 Jan; 53(1):155-162. PubMed ID: 25416858
[TBL] [Abstract][Full Text] [Related]
19. Prenatal treatment with EGCG enriched green tea extract rescues GAD67 related developmental and cognitive defects in Down syndrome mouse models.
Souchet B; Duchon A; Gu Y; Dairou J; Chevalier C; Daubigney F; Nalesso V; Créau N; Yu Y; Janel N; Herault Y; Delabar JM
Sci Rep; 2019 Mar; 9(1):3914. PubMed ID: 30850713
[TBL] [Abstract][Full Text] [Related]
20. Principal Component Analysis of the Effects of Environmental Enrichment and (-)-epigallocatechin-3-gallate on Age-Associated Learning Deficits in a Mouse Model of Down Syndrome.
Catuara-Solarz S; Espinosa-Carrasco J; Erb I; Langohr K; Notredame C; Gonzalez JR; Dierssen M
Front Behav Neurosci; 2015; 9():330. PubMed ID: 26696850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
